AYTU vs. SCS

Last updated Jun 9, 2026

AYTU (Aytu BioPharma, Inc.) and SCS (Steelcase Inc.) are both stocks. AYTU operates in Drug Manufacturers - Specialty & Generic (Healthcare), while SCS operates in Business Equipment & Supplies (Industrials). At a 0.10 correlation, their price movements are largely independent.

Performance

AYTU vs. SCS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aytu BioPharma, Inc. (AYTU) and Steelcase Inc. (SCS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

AYTU

• 1D: 1.78%
• 1M: -8.40%
• YTD: -11.92%
• 6M: 2.23%
• 1Y: 14.50%
• 3Y*: 12.70%
• 5Y*: -53.73%
• 10Y*: —

SCS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

AYTU vs. SCS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AYTU Aytu BioPharma, Inc.	-11.92%	52.94%	-40.14%	-24.87%	-86.00%	-77.42%	-38.35%	22.41%	-98.22%	-88.85%
SCS Steelcase Inc.	0.00%	39.89%	-9.11%	97.75%	-36.31%	-9.87%	-31.43%	42.60%	1.19%	-5.31%

Correlation

The correlation between AYTU and SCS is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.08
Correlation (5Y) Calculated over the trailing 5-year period	0.15
Correlation (All Time) Calculated using the full available price history since Feb 2, 2017	0.10

Fundamentals

Market Cap AYTU : $24.07M SCS : $1.93B
EPS AYTU : -$2.91 SCS : $0.80
PS Ratio AYTU : 0.47 SCS : 0.59
PB Ratio AYTU : 0.68 SCS : 1.89
Total Revenue (TTM) AYTU : $56.60M SCS : $3.26B
Gross Profit (TTM) AYTU : $36.14M SCS : $1.09B
EBITDA (TTM) AYTU : -$27.34M SCS : $208.30M

Return for Risk

AYTU vs. SCS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AYTU

AYTU Risk / Return Rank: 51
AYTU Sharpe Ratio Rank: 52
AYTU Sortino Ratio Rank: 49
AYTU Omega Ratio Rank: 49
AYTU Calmar Ratio Rank: 52
AYTU Martin Ratio Rank: 53

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AYTU vs. SCS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aytu BioPharma, Inc. (AYTU) and Steelcase Inc. (SCS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AYTU	SCS	Difference
Sharpe ratio: Return per unit of total volatility	0.27	—	—
Sortino ratio: Return per unit of downside risk	0.75	—	—
Omega ratio: Gain probability vs. loss probability	1.10	—	—
Calmar ratio: Return relative to maximum drawdown	0.41	—	—
Martin ratio: Return relative to average drawdown	0.97	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	AYTU	SCS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.27	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.63	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.36	—	—

Drawdowns

Drawdown Indicators

	AYTU	SCS	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-35.47%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-70.24%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-99.12%	—	—
Current Drawdown Current decline from peak	-100.00%	—	—
Average Drawdown Average peak-to-trough decline	-95.15%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	14.92%	—	—

Volatility

Volatility by Period

	AYTU	SCS	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.09%	—	—
Volatility (6M) Calculated over the trailing 6-month period	33.39%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	55.06%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.66%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	188.20%	—	—

Dividends

AYTU vs. SCS - Dividend Comparison

Neither AYTU nor SCS has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AYTU Aytu BioPharma, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SCS Steelcase Inc.	1.24%	1.86%	4.23%	2.22%	6.93%	4.56%	2.73%	2.83%	3.64%	3.36%	3.31%	2.27%

Financials

AYTU vs. SCS - Profitability Comparison

The chart below illustrates the profitability comparison between Aytu BioPharma, Inc. and Steelcase Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AYTU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a gross profit of 7.60M and revenue of 12.41M. Therefore, the gross margin over that period was 61.2%.

SCS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Steelcase Inc. reported a gross profit of 312.10M and revenue of 897.10M. Therefore, the gross margin over that period was 34.8%.

AYTU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported an operating income of -4.06M and revenue of 12.41M, resulting in an operating margin of -32.8%.

SCS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Steelcase Inc. reported an operating income of 53.10M and revenue of 897.10M, resulting in an operating margin of 5.9%.

AYTU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a net income of -5.62M and revenue of 12.41M, resulting in a net margin of -45.3%.

SCS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Steelcase Inc. reported a net income of 35.00M and revenue of 897.10M, resulting in a net margin of 3.9%.

Frequently Asked Questions

Can I hold both AYTU and SCS in my portfolio?

AYTU and SCS have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.